Deals In March MyungMoon Bio To Sell ACell's Wound Matrix Products In South Korea ACell Inc. granted MyungMoon Bio Co. Ltd. exclusive rights to market and distribute its wound management matrix pr
A device used in cardiac surgery and a powered-arm prosthesis will both be regulated as moderate-risk, class II devices, US FDA affirmed in a pair of Oct. 17 Federal Register notices. Both classificat
In July, the US FDA had its most active month of 2016 so far in approvals of novel device or indications, with 10 original and panel-track PMAs OK'd during the month, and another three de novo class
How do you solve a problem like mitral regurgitation (MR)? MR afflicts over 4 million people in the US alone. Many of those with worse disease have no good treatment options, while for others, the gol